Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5695326 | 1.00 | NR5A1 (0.53) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL6679672 | 1.00 | NR5A1 (0.53) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL3599892 | 0.98 | NR5A1 (0.50) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL2677998 | 0.94 | LTA4H (0.46) | NR5A1TP53TSHRLTA4HGAA | |
| SCHEMBL28224237 | 0.93 | LTA4H (0.44) | NR5A1TP53TSHRLTA4HGAA | |
| SCHEMBL21268351 | 0.91 | LTA4H (0.43) | NR5A1TSHRLTA4HGAARAB9A | |
| SCHEMBL7688412 | 0.90 | NR5A1 (0.50) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL7690618 | 0.90 | NR5A1 (0.46) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL21268379 | 0.87 | NQO1 (0.46) | NR5A1TP53TSHRLTA4HNPC1 | |
| SCHEMBL1404319 | 0.87 | LTA4H (0.44) | NR5A1LTA4HNPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102816130-B | Thiazole compound and use thereof | OTSUKA PHARMA CO LTD | 2015-05-06 | — | — | CN | disclosed |
| US-8450352-B2 | Thiazole compounds and their use for inhibiting phosphodiesterase 4, TNF-α, and IL-4 | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20100094002-A1 | Thiazole Compound and Use Thereof | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-04-15 | — | — | US | disclosed |
| US-7655680-B2 | (E)-3-[2-(3,4-diethoxyphenyl)thiazole-4-yl]-1-(2-methoxyphenyl)propenone; inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4; atopic dermatitis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20080039511-A1 | Thiazole Compound and Use Thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1748044-A1 | THIAZOLE COMPOUND AND USE THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094002-A1 | Thiazole Compound and Use Thereof | PDE3B, IL4, PDE4A | NR5A1 833/4885TP53 1864/4885TSHR 1124/4885 |
| US-20080039511-A1 | Thiazole Compound and Use Thereof | PDE3B, PDE3A, PDE4A | NR5A1 1561/4885TP53 4605/4885TSHR 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.